Navigation Links
Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
Date:11/3/2008

LAS VEGAS, Nov. 3 /PRNewswire/ -- Altogen Biosystems (http://www.altogen.com) announced launch of novel Nanoparticle-based transfection reagent for use in laboratories and research facilities for animal testing. Transfection is one of the major laboratory methods used to introduce DNA and RNA molecules into cells and tissues. This technique makes it possible to cross the cellular barriers and deliver a gene or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes.

The company has previously developed lipid- and polymer-based in vivo transfection reagents (http://www.altogen.com/mirna.htm) used for testing pharmaceuticals in animals. Altogen Biosystems recently developed novel nanoparticles biotechnology that allows highly efficient delivery of various biomolecules into animal tissues via systemic administration, as well as intraperitoneal and direct intratumoral injections.

Altogen Biosystems is focusing on commercializing pharma- and bio-technologies, as well as providing custom laboratory research services. The company now offers such innovative services as generation of stably-transformed cell lines in 28-days, as well as gene silencing and RNAi services (http://www.altogen.com/support.htm).

About Altogen Biosystems

Altogen Biosystems is a life sciences company located in Las Vegas, Nevada. The company is dedicated to the engineering, marketing and manufacture of transfection reagents and kits for intracellular and tissue-targeted delivery of biomolecules (http://www.altogen.com).

Altogen Custom Services focus on providing specialized biotechnology and pharmaceutical services, including generation of stable cell lines, gene silencing and RNA Interference (RNAi) services, assay development, library screening, and transfection services (http://www.altogen.com/support.htm).


'/>"/>
SOURCE Altogen Biosystems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
2. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
3. Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device
4. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
5. Open Biosystems Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
6. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
7. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
8. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
9. Primera Biosystems Raises $21 Million in Series B Private Round
10. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
11. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... findings on what they believe could be a new and helpful biomarker for ... research. Click here to read it now. , Biomarkers are components ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):